Adherence and preexisting major protease inhibitor resistance mutations are associated with virologic failure of a dual-class antiretroviral regimen with inhibitors of HIV-1 viral protease and integrase

Journal of the International Association of Physicians in AIDS Care

Volumn 11, Issue 1, 2012, Pages 34-39

  Gardner, Edward M ^a,b   Melendez, Andre G ^b   Astiz, Maria ^b   Bray, Kimberly ^a,b  

^a DENVER PUBLIC HEALTH   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

adherence; HIV; integrase inhibitor; protease inhibitor; treatment outcomes

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA;

ADULT; ARTICLE; BIVARIATE ANALYSIS; CLINICAL ARTICLE; CONFIDENCE INTERVAL; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOGISTIC REGRESSION ANALYSIS; MALE; MUTATION; PATIENT COMPLIANCE; PHARMACY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK;

ADULT; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MUTATION; PYRROLIDINONES; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84856905286     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109711422124     Document Type: Article

References (18)

1. Ruane PJ, Alas B, Wolf PR. Dual maintenance therapy with raltegravir BID with atazanavir qD (RAL/ATV) in patients with no prior PI resistance and intolerance to other ARV regimens: preliminary report.. :
2. Allavena C, Mounoury O, Rodallec A, Reliquet V, Billaud E, Raffi F. Efficacy and safety of an NRTI-sparing dual regimen of raltegravir and ritonavir-boosted protease inhibitor in a triple antiretroviral class-experienced population. HIV Clin Trials. 2009 ; 10 (5). 337-340
3. Ripamonti D, Maggiolo F, d'Avolio A, et al. Steady-state pharmacokinetics of Atazanavir (200 mg BID) when combined with Raltegravir (400 mg BID) in HIV-1 infected adults..:
4. Cordery DV, Hesse K, Amin J, Cooper DA. Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients. Antivir Ther. 2010 ; 15 (7). 1035-1038
5. Capetti AF, Piconi S, Landonio S, Rizzardini G, Perno CF. Is dual therapy with raltegravir and protease inhibitors a feasible option in rescue strategy in HIV-1 infection?. J Acquir Immune Defic Syndr. 2009 ; 50 (2). 233-234
6. Gupta S, Lataillade M, Farber S, Kozal MJ. Raltegravir with unboosted atazanavir 300 mg twice daily in antiretroviral treatment-experienced participants. J Int Assoc Physicians AIDS Care (Chic). 2009 ; 8 (2). 87-92
7. Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008 ; 358 (20). 2095-2106 (Pubitemid 351679596)
8. Gabow P, Eisert S, Wright R. Denver Health: a model for the integration of a public hospital and community health centers. Ann Intern Med. 2003 ; 138 (2). 143-149 (Pubitemid 36222502)
9. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr. 2005 ; 40 (3). 294-300 (Pubitemid 41533069)
10. Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med. 2009 ; 17: 138-145
11. Steigbigel RT, Cooper DA, Teppler H, et al. Long-term efficacy and safety of Raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis. 2010 ; 50 (4). 605-612
12. Reynes J, Lawal A, Pulido F, et al. Lopinavir/ritonavir (LPV/r) combined with raltegravir (RAL) demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naive HIV-1 infected subjects..:
13. Taiwo B, Zheng S, Gallien S, et al. Results from a single arm study of DVR/r + RAL in treatment-naive HIV-1-infected Patients (ACTG A5262)..:
14. Zhu L, Butterton J, Persson A, et al. Pharmacokinetics and safety of twice-daily atazanavir 300 mg and raltegravir 400 mg in healthy individuals. Antivir Ther. 2010 ; 15 (8). 1107-1114
15. Fabbiani M, Di Giambenedetto S, Ragazzoni E, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: potential role for an unexpected drug interaction. Pharmacol Res. 2010 ; 63 (3). 249-253
16. Gardner EM, Burman WJ, Steiner JF, Anderson PL, Bangsberg DR. Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS. 2009 ; 23 (9). 1035-1046
17. ShaferRWRheeSYZioniRHIV drug resistance database, StanfordUniversity. http://hivdb.stanford.edu/pages/algs/sierra-mutation.html. Accessed October 4, 2010.
18. Cooper DA, Steigbigel RT, Gatell JM, et al. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med. 2008 ; 359 (4). 355-365